Mirati Therapeutics (MRTX) PT Raised to $133 at Stifel, Sees Multiple Reason to "Lean Bullish" Despite Market Skepticism
Tweet Send to a Friend
Stifel analyst Ben Burnett raised the price target on Mirati Therapeutics (NASDAQ: MRTX) to $133.00 (from $115.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
